IDP-001 / InduPro - LARVOL DELTA

Discovery and optimization of IDP-001, a bispecific ADC targeting EGFR and CDCP1 (AACR 2025) - "IDP-001 has potent in vitro cytotoxic activity against cancer cell lines with varying target expression levels. IDP-001 is a first-in-class bispecific ADC with the potential for a wider therapeutic window and best-in-class efficacy."

Oncology • CDCP1 • EGFR

Membrane interactomics (MInt) platform identifies EGFR and CDCP1 as effective co-targets for bispecific antibody drug conjugate IDP-001 (AACR 2025) - "IDP-001 is effective in vitro against a panel of cancer cell lines of varying target expression levels, including Osimertinib resistant EGFR mutant NSCLC. 3) Law ME, et al. Breast Cancer Res 18 (2016) 80."

Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CDCP1 • EGFR

Application of a membrane interactomics (MInt) platform for novel surface target discovery (AACR 2025) - "This platform has led to multiple preclinical programs, including IDP-001, a bispecific ADC targeting EGFR and CDCP1 in solid tumors.Here, we showcase our discovery engine for novel target identification as a powerful method for uncovering druggable protein targets with improved therapeutic windows. This approach has the potential to expand the repertoire of cancer targets and enable the next generation of bispecific therapeutics."

Oncology • Solid Tumor • CDCP1 • EGFR

IDP-001 is a potent bispecific ADC with in vivo activity against mouse xenograft tumor models expressing EGFR and CDCP1 (AACR 2025) - "IDP-001 is a first-in-class bispecific ADC with the potential for broad therapeutic activity and best-in-class efficacy. These encouraging in vivo results support advancement of IDP-001 to non-human primate studies."

Preclinical • Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • CDCP1 • EGFR